menu search

Libtayo® (cemiplimab) neoadjuvant treatment demonstrates encouraging event-free survival in patients with resectable cutaneous squamous cell carcinoma (cscc)

89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 tr...

October 21, 2023, 12:48 pm

Regeneron to showcase progress from innovative oncology portfolio in several difficult-to-treat cancers at esmo

Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous ...

October 15, 2023, 10:05 pm

Bristol myers' (bmy) opdivo positive in late-stage nsclc study

Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery...

September 22, 2023, 1:31 pm

Replimune: q4 2023 data readouts of rp1 makes this a must watch

Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous s...

August 14, 2023, 5:28 pm

Atossa therapeutics hits 30% enrollment for (z)-endoxifen arm of ongoing i-spy 2 clinical trial

Atossa Therapeutics Inc (NASDAQ:ATOS), which is developing medicines aimed at oncology and breast cancer, revealed that six patients have been dosed w...

June 28, 2023, 11:01 am

Atossa completes enrollment of pharmacokinetic run-in cohort in phase 2 evangeline clinical trial evaluating (z)-endoxifen as a neoadjuvant treatment for er+ / her2- breast cancer

SEATTLE, June 12, 2023 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative...

June 12, 2023, 1:15 pm

Atossa finishes pk run-in cohort enrollment in breast cancer trial

Atossa Therapeutics Inc (NASDAQ:ATOS), which is developing medicines aimed at oncology and breast cancer, revealed that the pharmacokinetic (PK) run-i...

June 12, 2023, 10:52 am

Bristol myers' (bmy) opdivo data positive for neoadjuvant nsclc

Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with che...

April 12, 2022, 4:33 pm

Natera to present data from the beatrice and i-spy2 trials in early-stage tnbc and hr+/her2- breast cancer at the 2022 aacr annual meeting

Signatera ctDNA dynamics are both predictive and prognostic in neoadjuvant TNBC. Lead time up to 30 mon...

April 11, 2022, 7:33 am

Angle's parsortix used to analyse and inform treatment for aggressive form of breast cancer

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) highlighted that researchers at a leading cancer research institute successfully used the company's Parsortix system ...

March 25, 2022, 3:49 am


Search within

Pages Search Results: